IR – Biovica

Delårsrapport 2 – Lovande resultat publicerade på ESMO

tkrkv 221/22kv 220/21maj-okt 21/22maj-okt 20/21Helår20/21Nettoomsättning268446493842 077Rörelseresultat-14 314-8 285-26 552-16 950-40 181Periodens resultat-14 388-8 208-26 613-16 581-39 482Resultat per aktie efter utspädn.-0,51-0,29-0,93-0,59-1,39Väsentliga händelser under andra kvartaletBiovica förstärker ledningsgruppen med Warren Cresswell, President Americas, med ansvar för lanseringen av DiviTum®TKa i USA.Uppdatering om fördröjning i FDA-processen.Lovande DiviTum®TKa-resultat från Novartis BioItaLEE-studie presenterades vid ESMO.DiviTum®TKa-resultat från SWOG-studien publicerade i [...]

2021-12-01T07:30:00+01:00December 1st, 2021 07:30|

Q2 Interim report – Promising results published at ESMO

SEK 000sQ221/22Q220/21May-Oct 21/22May-Oct 20/21Full year20/21Net sales268446493842,077Operating profit (loss)-14,314-8,285-26,552-16,950-40,181Profit (loss) for the period-14,388-8,208-26,613-16,581-39,482Earnings per share after dilution-0.51-0.29-0.93-0.59-1.39Significant events during the second quarterBiovica has strengthened its management team with the addition of Warren Cresswell, President Americas, with responsibility for the launch of DiviTum®TKa in the USA.Update on delay in the FDA process.Promising DiviTum®TKa results from the Novartis [...]

2021-12-01T07:30:00+01:00December 1st, 2021 07:30|

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.

2021-11-24T08:00:00+01:00November 24th, 2021 08:00|

Biovica meddelar start av TK IMPACT studien vid Washington University of St Louis

Biovica , verksamt inom cancerdiagnostik, meddelar idag att bolaget TK IMPACT studien startar, en prövarinitierad prospektiv klinisk studie vid Washington University of St Louis som utvärderar den kliniska användbarheten av Biovicas blodbaserade biomarkörstest DiviTum®TKa vid monitorering av patienter med spridd bröstcancer.

2021-11-24T08:00:00+01:00November 24th, 2021 08:00|

Tre studier av Biovicas DiviTum®TKa presenteras på SABCS 2021

Biovica, verksamt inom cancerdiagnostik, meddelar idag att resultaten från tre studier med DiviTum®TKa, inklusive en budgeteffektmodell, kommer att presenteras vid världens största bröstcancerkonferens, San Antonio Breast Cancer Symposium (SABCS), i början av december. Studierna omfattar nästa generations CDK-hämmare, samuraciclib från Carrick Therapeutics, biomarkörstudien PROMISE utförd vid Mayo Clinic och DiviTum®TKas budgeteffektmodell. Alla studier fokuserar på DiviTum®TKas roll vid monitorering av behandling av spridd bröstcancer.

2021-11-19T16:05:00+01:00November 19th, 2021 16:05|

Biovica’s DiviTum®TKa in three studies at SABCS 2021

Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.

2021-11-19T16:05:00+01:00November 19th, 2021 16:05|

Biovica’s DiviTum®TKa results published in Journal of Medical Economics

Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model’s results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.

2021-11-16T09:15:00+01:00November 16th, 2021 09:15|

Biovicas DiviTum®TKa-resultat publicerade i Journal of Medical Economics

Biovica, verksamt inom cancerdiagnostik, meddelade idag att resultaten av en DiviTum®TKa-budgetmodell har publicerats i Journal of Medical Economics. Publikationen utökar de data som presenterades vid ISPOR 2021. Resultaten från modellen visar att monitorering med DiviTum®TKa kan ge besparingar på upp till tre gånger den extra kostnaden jämfört med nuvarande behandling av patienter med spridd bröstcancer.

2021-11-16T09:15:00+01:00November 16th, 2021 09:15|

Kommuniké från extra bolagsstämma i Biovica International

Extra bolagsstämman i Biovica International AB ("Biovica" eller "Bolaget") hölls idag den 12 oktober 2021 varvid aktieägarna fattade följande beslut.

2021-10-12T13:35:00+02:00October 12th, 2021 13:35|

Announcement from Biovica International’s extra general meeting

The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 12 October 2021 and the following resolutions were passed by the meeting.

2021-10-12T13:35:00+02:00October 12th, 2021 13:35|